Matrix metalloproteinase-9 (MMP9), expressed predominantly by fast motor neurons and thought to precondition them to become highly vulnerable to ALS triggers, is a potential target for the treatment of sporadic ALS. This evidence concerns the gene MMP9 and amyotrophic lateral sclerosis.